SPONSOR
UNICANCER
Total Trials
8
Recruiting
8
Phases
Phase 3, Phase 2
Conditions studied: Prostatic Cancer, Castration-ResistantLung Cancer MetastaticRenal Cell CarcinomaHead and Neck CancerTriple Negative Breast CancerMerkel Cell CarcinomaHepatocellular CarcinomaMelanomaUrothelial CarcinomaColorectal Carcinoma With Microsatellite Instability
UNICANCER is a clinical research sponsor with 8 registered studies on ClinicalTrials.gov, of which 8 are actively recruiting participants. Research covers conditions including Prostatic Cancer, Castration-Resistant, Lung Cancer Metastatic, Renal Cell Carcinoma, Head and Neck Cancer.
The trial portfolio spans Phase 3, Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — UNICANCER
How many clinical trials has UNICANCER sponsored?
ClinicalMetric currently tracks 8 clinical trials sponsored by UNICANCER, of which 8 are actively recruiting participants. These trials cover conditions including Prostatic Cancer, Castration-Resistant, Lung Cancer Metastatic, Renal Cell Carcinoma. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does UNICANCER research focus on?
UNICANCER clinical trials span Prostatic Cancer, Castration-Resistant, Lung Cancer Metastatic, Renal Cell Carcinoma, Head and Neck Cancer, Triple Negative Breast Cancer, and additional conditions. The research pipeline includes Phase 3, Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a UNICANCER clinical trial?
To participate in a UNICANCER trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all UNICANCER trials with current recruitment status updated daily.
Clinical Trials by UNICANCER
NCT06276465 Phase 3
Recruiting
Treatment With Darolutamide +/- Radiation Therapy for Patients With a Castration Resistant Cancer and Metastases Detected by Functional Imaging
Prostatic Cancer, Castration-Resistant
NCT05078047 Phase 3
Recruiting
Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO
Lung Cancer Metastatic
NCT03848052
Recruiting
Evolution of the Therapeutic Care in Lung Cancer in France Since 2015 (ESME LC)
Lung Cancer
NCT06475352 Phase 2
Recruiting
Dose Individualization of Chemotherapy in Patients With Gastrointestinal Cancers Lacking a Specific Liver Enzyme
Digestive Cancer
NCT05476796 Phase 2
Recruiting
Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer
Gastric Adenocarcinoma
NCT05443087
Recruiting
TARGETed Therapy Drug MONITOring in DIGestive Oncology
Digestive Cancer
NCT05297617 Phase 2
Recruiting
Deescalation of Endocrine Therapy Duration in Women With HR+ HER2- Breast Cancer at Very Low Risk
Breast Cancer
NCT06625970 Phase 3
Recruiting
Study Evaluating the Efficacy and Safety of Darolutamide and Stereotactic Dose Escalated Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of Relapse
High Risk Prostate Carcinoma
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology